Steroid 5α-reductase inhibitor treatment for benign prostatic hyperplasia

Drugs of the Future

Volumn 19, Issue 7, 1994, Pages 646-650

  Audet, P R ^a   Baine, N H ^a   Benincosa, L J ^a   Holt, D A ^a   Wier, P J ^a   Rappaport, E B ^a   Metcalf, B W ^a   Levy, M A ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; ANDROSTANOLONE; EPRISTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE PROPIONATE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; CLINICAL TRIAL; DOG; DOSE RESPONSE; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PROSTATE HYPERTROPHY; RAT;

EID: 0028083310     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1994.019.07.257360     Document Type: Article

References (0)